Revvity, Inc. (RVTY) Stock Price & Analysis
Revvity, Inc. (RVTY) closed at USD 157.36 on Thursday, October 22, 2026, up 0.48% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 156.61; the Oct 22, 2026 session ranged USD 154.89–161.52 on volume of 1,779,722 shares. Market capitalization is $17.56B, with a 52-week range of USD 81.22–166.25 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:15 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RVTY.md
Key facts (RVTY)
- Last four reported quarters (through Jul 5, 2026): revenue $2.91B, net income $238M (8.2% margin), free cash flow $558M (SEC filings).
- Valuation: P/E 73.9x (avg 39.1x at the last 3 fiscal year-ends).
- Earnings quality: non-operating income -$98.1M vs operating income $359M over the last four quarters; P/E excluding non-operating income ≈53.7x (estimate: non-operating income taxed at the company's 9% effective rate).
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $1.3M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.78 on a 1–5 scale) (18 analysts), mean target USD 147.53 (range 110–175).
- Total return with dividends: 1Y +61.6% vs S&P 500 +14.9%; 5Y -9.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.3, revenue estimate $695M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RVTY)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.83B | $3.31B | $2.75B | $2.76B | $2.86B | $2.91B |
| Gross profit | $2.43B | $1.99B | — | — | — | — |
| Operating income | $1.26B | $743M | $301M | $347M | $357M | $359M |
| Net income | $943M | $569M | $693M | $270M | $241M | $238M |
| EPS (diluted) | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 | — |
| Free cash flow | $1.32B | $594M | $9.9M | $542M | $509M | $558M |
| Gross margin | 63.6% | 60.1% | — | — | — | — |
| Operating margin | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% | 12.3% |
| Net margin | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% | 8.2% |
| Revenue growth | +1.2% | -13.5% | -16.9% | +0.2% | +3.7% | — |
| Cash + short-term investments | $603M | $454M | $1.60B | $1.16B | — | — |
| Total debt | $4.98B | $4.39B | $3.90B | $3.17B | $3.24B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 5, 2026) (RVTY)
P/E 73.9x · P/E ex non-operating (est.) ≈53.7x · P/S 6.0x · P/FCF 31.5x · P/B 2.4x · FCF yield 3.18% · Earnings yield 1.35% · Dividend yield (paid, TTM) 0.18% · Buyback yield (TTM) 2.71%
P/E at fiscal year-ends: Dec 2025 46.8x, Dec 2024 50.7x, Dec 2023 19.7x.
Insider sales (SEC Form 4, open-market, last ~7 months) (RVTY)
5 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gonzales Anita | VP and CAO | 84 | $13K | 1.2% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21 | Krakowiak Maxwell | Please See Remarks | 1,631 | $236K | 9.9% | Yes (adopted May 19, 2026) | Too little history (no open-market trades in 2024 or 2025) |
| 2026-09-16 | Vohra Tajinder S | Please See Remarks | 7,330 | $1.0M | 52.5% | Yes (adopted May 15, 2026) | Too little history (no open-market trades in 2023) |
| 2026-07-20 | Gonzales Anita | Vice President and CAO | 85 | $9K | 1.2% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-04-20 | Gonzales Anita | Vice President and CAO | 80 | $7K | 1.1% | Yes (adopted November 7, 2025) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (RVTY)
Consensus Hold (mean 2.78 on a 1–5 scale), 18 analysts; mean target USD 147.53 (low 110, high 175).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $130 → $175 |
| 2026-10-07 | Barclays | Target raised | Equal-Weight | $115 → $160 |
| 2026-10-06 | William Blair | Initiated | Outperform | |
| 2026-09-04 | Keybanc | Target raised | Overweight | $125 → $165 |
| 2026-09-01 | RBC Capital | Initiated | Sector Perform | $135 |
| 2026-08-05 | Evercore ISI Group | Target raised | Outperform | $125 → $126 |
| 2026-07-06 | Evercore ISI Group | Target raised | Outperform | $110 → $125 |
Total return (dividends reinvested) (RVTY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +61.6% | -9.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +61.9% | -2.0% |
| Volatility (annualized) | 38.7% | 33.8% |
| Max drawdown | -30.1% (Jan 2026→Apr 2026) | -58.4% (Dec 2021→Sep 2025) |
RVTY revenue by business segment (quarter ended Jul 5, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Diagnostics | $371.0M | 50.8% | +4.7% |
| Life Sciences | $358.7M | 49.2% | -2.0% |
| Total revenue | $729.7M | 100% | — |
RVTY revenue by product line (quarter ended Jul 5, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $603.4M | 82.7% | -1.2% |
| Service | $126.3M | 17.3% | +15.2% |
| Total revenue | $729.7M | 100% | — |
RVTY revenue by region (quarter ended Jul 5, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $325.6M | 44.6% | +0.6% |
| Europe | $229.0M | 31.4% | +12.5% |
| Asia | $175.1M | 24.0% | -9.3% |
| Total revenue | $729.7M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RVTY suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | UPS (UPS) | “We ship a significant portion of our products to our customers through independent package delivery and import/export companies, including UPS and Federal Express in the United States;” |
| Partner | Microsoft (MSFT) | “From increased collaboration to securely accessible data, the Signals NotebookTM offering accelerates research and development workflows, increases collaboration, integrates with Microsoft Office and more.” |
Quoted from the company's 10-K filed Feb 24, 2026.
Companies that name RVTY in their SEC reports
| Relationship to RVTY | Company | Filing | Sentence |
|---|---|---|---|
| partner | Quanterix Corp (QTRX) | 10-K Mar 2, 2026 | “In September 2018, in connection with the acquisition of the Quantitative Pathology Solutions ("QPS") technology from PKI, Akoya entered into a license and royalty agreement with PKI, Cambridge Research, and VisEn Medical, (collectively, the "Licensor"), pursuant to which the Licensor granted Akoya an exclusive, nontransferable, sublicensable (subject to certain conditions), worldwide license within certain fields…” |
RVTY company outlook (results filed Aug 4, 2026)
- “For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.”
- “Guidance for the full year 2026 for pro forma organic revenue growth and pro forma adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures.”
- “Webcast Information The Company will discuss its second quarter 2026 results and its outlook for business trends during a webcast on August 4, 2026, at 7:30 a.m.”
Quoted word-for-word from the SEC 8-K results press release.
RVTY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.30 | $1.31 | -1.1% | $694.7M | 16 |
| Next quarter (ends Dec 2026) | $1.61 | $1.67 | -3.3% | $759.5M | 15 |
| Current fiscal year (ends Dec 2026) | $5.35 | $5.24 | +2.0% | $2.85B | 17 |
| Next fiscal year (ends Dec 2027) | $5.89 | $5.83 | +1.2% | $3.01B | 17 |
RVTY options: expected move
Options price a move of about ±12.4% (±$19.45) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±5.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 55.3% | ±12.4% |
| Dec 18, 2026 | 56 | 48.1% | ±15.0% |
| Jan 15, 2027 | 84 | 45.2% | ±17.3% |
| Mar 19, 2027 | 147 | 44.5% | ±22.3% |
| May 21, 2027 | 210 | 44.7% | ±26.8% |
| Jun 17, 2027 | 237 | 44.2% | ±28.2% |
30-day implied volatility 55% vs 39.9% realized over the last 30 trading days. Put/call ratio (volume) 0.33. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:15 UTC)
| Price | USD 157.36 |
|---|---|
| Change | ▲ 0.48% (up) |
| Previous Close | USD 156.61 |
| Open | USD 156.18 |
| Day Range | USD 154.89 – 161.52 |
| 52-Week Range | USD 81.22 – 166.25 |
| Volume | 1,779,722 shares |
| Market Cap | $17.56B |
| Exchange | NYQ |
Technical Analysis (RVTY)
Nexqual's technical model rates RVTY "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:15 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.94 (neutral) |
| vs SMA50 | Above (USD 139.26) |
| MACD | 4.53 (positive) |
Analyst Ratings (RVTY)
Wall Street analysts rate RVTY "Hold" based on 18 analysts, with a mean price target of USD 147.53 (range USD 110–175), per Nexqual as of October 23, 2026 at 09:15 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 147.53 |
| High Target | USD 175 |
| Low Target | USD 110 |
| Buy / Hold / Sell | 6 / 11 / 1 |
Earnings (RVTY)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 1.3 |
| Revenue Estimate | $694.74M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.41 vs est 1.22 ▲ beat |
| 2026-03-31 | USD 1.06 vs est 1.01 ▲ beat |
| 2025-12-31 | USD 1.7 vs est 1.58 ▲ beat |
| 2025-09-30 | USD 1.18 vs est 1.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Financials & Fundamentals (RVTY)
| Total Revenue | $2.91B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.30% |
| Gross Margin | +54.98% |
| Operating Margin | +17.05% |
| Profit Margin | +8.16% |
| ROE | +3.21% |
| Debt / Equity | 0.46 |
| Current Ratio | 1.8 |
| Total Cash | $1.02B |
| Total Debt | $3.34B |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $558.11M (19.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Financial Health Score (RVTY)
Nexqual rates Revvity, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:15 UTC.
| Growth | Mixed — Revenue +3.6% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 17% (last 12 months) |
| Balance Sheet | Solid — $1.02B cash vs $3.34B debt |
| Cash Flow | Strong — FCF $558M (last 4 quarters to Jul 2026, SEC), 19% margin |
| Efficiency | Weak — ROE 3%, ROA 2.4% |
Ownership (RVTY)
| Insider Ownership | +0.26% |
|---|---|
| Institutional Ownership | +103.88% |
| Shares Outstanding | 111.59M |
| Float | 102.49M |
| Short % of Float | +8.46% |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Leadership (RVTY)
Revvity, Inc. is led by Prahlad R. Singh, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:15 UTC.
| CEO, President & Director | Prahlad R. Singh |
|---|---|
| Senior VP & CFO | Maxwell Krakowiak |
| Senior Vice President of Global Operations | Tajinder S. Vohra |
| Senior Vice President & Chief Business Officer | Miriame Victor |
| Senior VP & Chief Scientific Officer | Madhuri Hegde FACMG |
Major Backers & Investors (RVTY)
Notable institutional backers of Revvity, Inc. include T. Rowe Price, Jupiter Topco LLC, Edgepoint Investment Group Inc., according to Nexqual as of October 23, 2026 at 09:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 16.37% |
| Jupiter Topco LLC | 7.74% |
| Edgepoint Investment Group Inc. | 7.66% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 5.15% |
| Price (T.Rowe) Associates Inc | 4.96% |
| Victory Capital Management Inc. | 3.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.82% |
| BlackRock | 6.86% |
| State Street | 3.89% |
| Dimensional Fund Advisors | 3.07% |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
From Revvity, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Legal & Regulatory Risks (Item 1A, quoted)
- The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
- We are subject to stringent data privacy and information security laws and regulations and changes in such laws or regulations, or our failure to comply with such requirements, could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
- Changes in governmental regulations may reduce demand for our products or increase our expenses.
- The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MEDP | Medpace Holdings, Inc. | USD 653.96 | ▼ 1.29% |
| CRL | Charles River Laboratories Inte | USD 339.66 | ▼ 1.51% |
| ICLR | ICON plc | USD 185.43 | ▲ 0.1% |
| GH | Guardant Health, Inc. | USD 162.94 | ▼ 2.23% |
| LH | Labcorp Holdings Inc. | USD 329.93 | ▲ 1.91% |
| DGX | Quest Diagnostics Incorporated | USD 243.28 | ▲ 1.82% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:15 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt